KRÁTKÉ SDĚLENÍ SHORT COMMUNICATION

Gender Differences in Clinical Presentation and Occurence of Sleep Disturbances in Patiens with Parkinson's Disease – a Population-based Study

Rozdiely medzi pohlaviami v klinických prejavoch a výskyte porúch spánku u pacientov s Parkinsonovou chorobou – populačná štúdia

Abstract

Sleep disturbances are one of the most common non-motor symptoms in patient with Parkinson's disease (PD) with community-based studies reporting prevalence data of 60%. Differences in symptoms between men and women have been reported. Aim: In the present study, we assessed whether there are gender differences in clinical presentation of PD and prevalence of sleep disturbances in individuals diagnosed in the Slovak Republic. Material and method: Questionnaires were distributed to participating neurologists and patients in outpatient practices across the Slovak Republic. Sociodemographic variables – gender, age, age at onset, disease severity according to Hoehn and Yahr stage, phenotype of the dominating symptom of Parkinson's disease and type of medication – were collected. The Slovak language version of the PDSS was used in a questionnaire to test sleep disturbances. Results: Data from 1,067 outpatients with PD were collected. Comparative analyses showed males and females not to be significantly different on the majority of the demographic and medical characteristics collected. Males had a slightly higher proportion of individuals with Hoehn and Yahr score 4 and, among those taking levodopa medication as monotherapy, males took significantly higher levodopa dose than females (p < 0.01). A significant difference in the distribution of PDSS subscores between males and females was observed on item 7 (distressing hallucinations at night) – score for males 8.22, for females 8.48, p < 0.05. Similar result was observed on item 8 (getting up to pass urine) – score for males 5.90, for females 6.53, p < 0.01.

Súhrn

Poruchy spánku patria k najčastejším non-motorickým prejavom u pacientov s Parkinsonovou chorobou (PCh), v populačných štúdiách je uvádzaný ich výskyt až u 60 % pacientov. Štúdie tiež uvádzajú rozdielnosť prejavov PCh medzi mužmi a ženami. *Ciel*: Zistiť, či sú u pacientov s PCh na Slovensku prítomné medzi pohlaviami rozdiely v klinických prejavoch PCh a výskyte porúch spánku. *Materiál a metódy:* Zisťovanie bolo robené dotazníkovou metódou s účasťou pacientov a neurológov z jednotlivých regiónov Slovenskej republiky. Dotazníky boli vyplňované počas rutinných kontrolných návštev. Boli zisťované socioekonomické premenné ako pohlavie, vek, vek pri začiatku ochorenia, stupeň poškodenia hodnotený škálou Hoehna a Yahrovej, dominujúci fenotyp ochorenia a používaná medikácia. Pri hodnotení porúch spánku bola použitá slovenská verzia dotazníka PDSS. *Výsledky:* Získali sme dáta od 1 067 pacientov. Pri porovnávacích analýzach neboli zistené podstatné rozdiely vo väčšine hodnotených parametrov. U mužov bol o niečo vyšší podiel pacientov s hodnotou škály Hoehna a Yahrovej 4 a boli zistené signifikantne vyššie dávky levodopy v monoterapii (p < 0,01). Významné rozdiely boli zistené v skóre škály PDSS pre hodnotenie rušivých halucinácií počas noci – skóre u mužov bolo 8,22, u žien 8,48 (p < 0,05). Podobný výsledok sme zaznamenali v skóre hodnotiacom nutnosť močenia počas noci – u mužov bolo skóre 5,90, u žien 6,53 (p < 0,01).

We thank all patients and neurologists in outpatient practices for their cooperation. We are also grateful to Mr. Helbich for help with statistical analysis.

Autoři deklarují, že v souvislosti s předmětem studie nemají žádné komerční zájmy.

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

Redakční rada potvrzuje, že rukopis práce splnil ICMJE kritéria pro publikace zasílané do biomedicínských časopisů.

The Editorial Board declares that the manuscript met the ICMJE "uniform requirements" for biomedical papers.

F. Cibulčík, A. Hergottová, K. Kračunová, J. Benetin

Department of Neurology, Slovak Medical University and University Hospital Bratislava, Slovak Republic

 \boxtimes

František Cibulčík, MD, PhD.
Department of Neurology
Slovak Medical University and
University Hospital Bratislava
Ružinovská 6
826 06 Bratislava
Slovak Republic
e-mail: cibulcik@hotmail.com

Accepted for review: 11. 8. 2014 Accepted for print: 20. 1. 2015

Key words

Parkinson's disease – gender differences – sleep

Klíčová slova

Parkinsonova choroba – pohlavné rozdiely – spánok

Introduction

Parkinson's disease (PD) is a neurodegenerative disorder characterized by movement dysfunction and non-motor impairment. More men than women are diagnosed with PD by a ratio of approximately 2:1 [1]. Differences in symptoms between men and women have been reported - rigidity and rapid eye movement behavior disorder are more often present in men, dyskinesias and depression in women [2]. Studies have reported developmental and functional differences of the nigrostriatal system associated with sex hormones between males and females [3]. Others suggest that estrogen may influence pathogenesis of PD and help to explain reduced incidence of PD in women [4].

Sleep disturbances are one of the most common non-motor symptoms in patient with PD in community-based studies reporting prevalence of 60% in PD patients, compared with 33% in healthy age- and sex-matched controls [5]. Gender differences have been found in the presence of rapid eye movements behavior disorder [6,7]. Sleep can by evaluated by history, scales and neurophysiological methods. Six scales were found to meet criteria for recommendation or suggestion [8]. One of them – The Parkinson's Disease Sleep Scale (PDSS) – is intended to screen for the presence of many different sleep disorders found in Parkinson's disease patients and provide a general impression of their severity [9]. In the present study, we assessed gender differences in clinical presentation of sleep disturbances, as evaluated by PDSS in individuals diagnosed with PD in the Slovak Republic.

Methods

Questionnaires were distributed to participating neurologists in outpatient prac-

tices across the Slovak Republic. Physicians and patients completed the questionnaire as part of the local documentation for routine clinical practice. After this time period, questionnaires were collected by the study coordinator.

Subjects

To be included, the patient had to be diagnosed with PD as defined by the United Kingdom Brain Bank Criteria [10] and be able to give an informed consent and complete the research questionnaire. Socio-demographic variables in the questionnaire – gender, age, age at onset, disease severity according to Hoehn and Yahr (H & Y) [11], phenotype of the dominating PD symptom and medication – were collected by the physicians using data from the patient interview and documentation.

Sleep disturbances testing

To test the sleep disturbances, the guestionnaire used the Slovak language version of the PDSS. Patients completed the PDSS based on the quality of their nocturnal sleep in the past week. The PDSS is composed of 15 items exploring eight aspects of sleep. Item 1 addresses the global quality of nocturnal sleep. Items 2–14 are related to the presence of nocturnal sleep disturbances and item 15 evaluates unexpected sleep during a day. The patient's response to each item is marked on a visual analogue scale ranging from always (0) to never (10), except for item 1 (awful - 0, to excellent - 10). Total PDSS score ranges from 0 to 150, where a higher score represents better quality of nocturnal sleep. Translation of the original PDSS to the Slovak language was carried out by experts involved in research on PD.

Statistical analysis

To compare gender groups, we used t-test (for continuous variables) and chi-squared or Fisher's exact test (for nominal variables). Significance level of 0.05 was used throughout the study.

Results

Data from 1,067 outpatients with PD were collected. Table 1 shows demographic, historical and clinical characteristics of the overall sample of patients by gender group. 50.3% of individuals in the sample were male, 49.7% were female. Comparative analyses showed males and females not to be significantly different on the majority of

mean age at evaluation, years (SD) mean age at symptomatic onset, years (SD) age groups (years) of symptomatic onset, n (%) < 40 40–49 12 (2.2) 3 (0.6) 50–59 82 (15.2) 74 (14.0) 60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) II 105 (19.5) 104 (19.6) III 176 (32.8) 178 (33.6) IIII 169 (31.5) 168 (31.8)		Male	Female	
mean age at symptomatic onset, years (SD) age groups (years) of symptomatic onset, n (%) < 40 40–49 12 (2.2) 3 (0.6) 50–59 82 (15.2) 74 (14.0) 60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) III 176 (32.8) 178 (33.6) IIII	number of patients, n (%)	538 (50.3)	529 (49.7)	
age groups (years) of symptomatic onset, n (%) < 40 40–49 12 (2.2) 3 (0.6) 50–59 82 (15.2) 74 (14.0) 60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 88–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) IIII	mean age at evaluation, years (SD)	68.5 (9.7)	68.4 (8.3)	
< 40 1 (0.2) 40–49 12 (2.2) 3 (0.6) 50–59 82 (15.2) 74 (14.0) 60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	mean age at symptomatic onset, years (SD)	63.9 (9.3)	63.7 (8.2)	
40-49 12 (2.2) 3 (0.6) 50-59 82 (15.2) 74 (14.0) 60-69 183 (34.1) 209 (39.5) 70-79 193 (35.9) 188 (35.5) 80-90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) 1 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	age groups (years) of symptomatic onset, n (%)			
50–59 82 (15.2) 74 (14.0) 60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	< 40	1 (0.2)	0	
60–69 183 (34.1) 209 (39.5) 70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	40–49	12 (2.2)	3 (0.6)	
70–79 193 (35.9) 188 (35.5) 80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	50–59	82 (15.2)	74 (14.0)	
80–90 63 (11.7) 52 (9.8) > 90 4 (0.7) 3 (0.6) mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	60–69	183 (34.1)	209 (39.5)	
> 90	70–79	193 (35.9)	188 (35.5)	
mean symptomatic disease duration, years (SD) 4.5 (4.7) 4.7 (5.5) phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	80–90	63 (11.7)	52 (9.8)	
phenotype of dominating symptom, n (%) tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	> 90	4 (0.7)	3 (0.6)	
tremor 272 (50.6) 265 (50.1) bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	mean symptomatic disease duration, years (SD)	4.5 (4.7)	4.7 (5.5)	
bradykinesia 135 (25.0) 126 (23.8) rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	phenotype of dominating symptom, n (%)			
rigidity 93 (17.3) 96 (18.2) other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	tremor	272 (50.6)	265 (50.1)	
other 38 (7.1) 42 (7.9) Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	bradykinesia	135 (25.0)	126 (23.8)	
Hoehn and Yahr stage, n (%) I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	rigidity	93 (17.3)	96 (18.2)	
I 105 (19.5) 104 (19.6) II 176 (32.8) 178 (33.6) III 169 (31.5) 168 (31.8)	other	38 (7.1)	42 (7.9)	
176 (32.8) 178 (33.6) 169 (31.5) 168 (31.8)	Hoehn and Yahr stage, n (%)			
III 169 (31.5) 168 (31.8)	l	105 (19.5)	104 (19.6)	
, ,	II	176 (32.8)	178 (33.6)	
IV 84 (15.6) 76 (14.5)	III	169 (31.5)	168 (31.8)	
	IV	84 (15.6)	76 (14.5)	

3 (0.6)

3 (0.5)

demographic and medical characteristics collected, p > 0.05. For both males and females, the mean age at the data collection was about 68 years, with proportional distribution of gender within the age subgroups (with the exception of the under 50 age group, where there were more males – 2.4% vs. 0.4% for males and females, respectively). The mean age at symptom onset was about 64 years. Disease duration was not significantly different between males and females (4.7 and 4.5 years, respectively). The majority of individuals in both gender groups reported tremor (about 50%) and bradykinesia (about 25%) as the dominant symptom of PD. The distribution of the dominating symptom type did not differ between males and females, p > 0.05. The majority of individuals were in the early to intermediate stage of PD (Hoehn and Yahr scale 3 or less) with proportional distribution between males and females. There was slightly higher proportion of males with Hoehn and Yahr scale of 4 (15.6% vs. 14.5% for males and females, respectively). The proportion of individuals taking specific subtypes of antiparkinsonian medication (levodopa only, an agonist only or a combined therapy) did not differ by sex. However, among those taking levodopa as monotherapy, males took significantly higher dose of levodopa than females (p < 0.01).


Table 2 shows the PDSS score components for males and females. Mean item score profiles are shown in Graph 1, for ease of comparison, similar data from the original study by Chaudhuri et al. [9] have been included. A significant difference in the distribution of PDSS subscores was observed between males and females on item 7 (distressing hallucinations at night) – score for males 8.22, for females 8.48, p < 0.05. Similar results were observed on item 8 (getting up to pass urine) – score for males 5.90, for females 6.53, p < 0.01.

Discussion

In our study, we investigated 1,067 patients, where the equal male and female distribution is in contradiction to large clinical cohorts [12,13]. The reason for this difference is not clear and should be explained in future. Significant difference in life expectancy between genders in Slovakia might be one of the possible explanations.

In our study, there was no significant difference in the mean age at symptom onset and age at evaluation between males and fe-

Tab. 2. PDSS in gender difference.			
	Male	Female	р
the overall quality of night's sleep	5.68	5.70	0.91
difficulty falling asleep each night	5.79	5.74	0.70
difficulty staying asleep	5.92	5.85	0.63
restlessness of legs or arms at night	6.82	6.58	0.24
fidgeting in bed	6.78	6.69	0.09
distressing dreams at night	7.42	7.45	0.92
distressing hallucinations at night	8.22	8.48	0.04*
getting up to pass urine	5.90	6.53	0.003**
incontinence of urine due to "off" symptoms	7.94	8.15	0.09
numbness or tingling which wake from sleep	7.05	7.18	0.51
painful muscle cramps whilst sleeping at night	6.90	7.12	0.25
wakeing up in the morning with painful posturing of arms or legs	6.94	7.16	0.30
tremor on waking	5.84	5.85	0.99
tiredness and sleepiness after waking in the morning	6.26	6.23	0.74
unexpected falling asleep during the day	7.20	7.27	0.88
total score	100.48	101.72	0.48



Graph 1. PDSS profiles of mean scores per item in Chaudhuri and colleagues, 2002 (grey line) and the current study (black line).

males, consistent with other PD samples [14]. Additionally, the distribution of symptom phenotype, duration and disease severity

according to the Hoehn and Yahr scale were similar between males and females. Thus, the disease progression rate from the onset

GENDER DIFFERENCES IN CLINICAL PRESENTATION AND OCCURENCE OF SLEEP DISTURBANCES

of initial symptoms to baseline appears to be the same for both males and females. Similar disease progression rates between genders were reported also in other longitudinal studies of clinical samples [15,16].

Graph 1 shows the profile of mean PDSS scores obtained in our study and the study by Chaudhuri et al. [9], revealing a discrepancy in terms of direction on items 2 and 15 only. These discrepancies can be explained by different composition of the samples – patients in the present study had shorter disease duration and lower Hoehn and Yahr scores than patients in the original paper.

With respect to gender differences, significant difference between males and females was observed in the distribution of PDSS subscores on item 7 (distressing hallucinations at night) p < 0.05, and on item 8 (getting up to pass urine) p < 0.01. Use of medication might be one of the possible explanations of the higher prevalence of night hallucinations among males. In a sample of nursing home patients with PD, men were more likely to receive antipsychotics, whereas women were more likely to receive antidepressants [17]. In the same sample, on the other hand, hallucinations were not more prevalent in either sex. Erroneous interpretation of vivid dreams as hallucinations might be another explanation. Ozekmekci at al. [7] noted that, of 35 PD patients with probable rapid eye movements behavior disorder (RBD), 77% were men. In the study of Yoritaka et al. [6] the presence of RBD in PD patients was associated with male gender with odds ratio of 2,469. In our study, statistically significantly more males got up to pass urine during night. The most common micturition abnormality in PD patients generally is related to detrusor hyperreflexia, while detrusor hypoactivity seems to be less prominent. In addition, paradoxical co-contractions of the urethral sphincter muscle has been described as a correlate of off-period voiding dysfunction in PD. Patients with mild detrusor hyperactivity may complain of nocturia with or without urgency during daytime, while urge incontinence is a feature of advanced PD only [18]; no gender differences in autonomic dysfunction causing micturition in PD patient have been reported. In the general population, nocturia is more prevalent in woman – in a recent Austrian study, mean nocturia score was 2.8 in men vs. 3.1 in women [19]; with 33%, nocturnal polyuria was the predominant cause of nocturia. The reason for male predominance in nocturia in our study remains unclear and needs to be evaluated in the future.

Several limitations of this study should be

- 1. the disease duration was relatively short (4.6 years) in this study;
- mainly PD patients in early and middle stages of the disease were enrolled, as indicated by the Hoehn and Yahr scale;
- to complete the questionnaire, we only chose PD subjects with sufficient cognitive ability, significantly narrowing the population in this study;
- 4. current antiparkinsonian and concomitant medication was not investigated in detail, the same is true for comorbidity.

Therefore, larger studies need to be done, expanding the authors' work to a broader spectrum of factors with possible impact on sleep quality.

In conclusion, this is one of the largest reported clinic-based study evaluating the relationship between the PD phenotype and gender and the first study evaluating the gender differences in sleep quality using the PDSS clinical scale. The majority of comparisons tended to highlight commonalities in the PD phenotype between males and females. The same is true for the majority of PDSS subscores, although significant difference in the distribution of PDSS subscores between males and females was observed on two of them – distressing hallucinations at night and getting up to pass urine were more frequent in male subjects . Further studies are needed to explain these differences.

References

1. Bordelon Y, Fahn S. Gender differences in movement disorders. In: Kaplan P (ed). Neurologic disease in women. New York: Demos 2006: 349–354.

- 2. Miller IN, Cronin-Golomb A. Gender differences in Parkinson's disease: clinical characteristics and cognition. Mov Disord 2010; 25(16): 2695–2703. doi: 10.1007/mds.23388
- **3.** Becker JB. Gender differences in dopaminergic function in striatum and nucleus accumbens. Pharmacol Biochem Behav 1999; 64(4): 803–812.
- **4.** Green PS, Simpkins JW. Neuroprotective effects of estrogens: potential mechanisms of action. Int J Dev Neurosci 2000: 18(4–5): 347–358.
- **5.** Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14(6): 922–927.
- **6.** Yoritaka A, Ohizumi H, Tanaka S, Hattori N. Parkinson's disease with and without REM sleep behaviour disorder: are there any clinical differences? Eur Neurol 2009; 61(3): 164–170. doi: 10.1159/000189269.
- 7. Ozekmekci S, Apaydin H, Kilic E. Clinical features of 35 patients with Parkinson's disease displaying REM behavior disorder. Clin Neurol Neurosurg 2005; 107(4): 306–309
- **8.** Högl B, Arnulf I, Comella C, Ferreira J, Iranzo A, Tilley B et al. Scales to assess sleep impairment in Parkinson's disease: critique and recommendations. Mov Disord 2010; 25(16): 2704–2716. doi: 10.1002/mds.23190.
- **9.** Chaudhuri KR, Pal S, DiMarco A, Whately-Smith C, Bridgman K, Mathew R et al. The Parkinson's disease sleep scale: a new instrument for assesing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002: 73(6): 629–635.
- **10.** Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992; 55(3): 181–184.
- **11.** Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17(5): 427–442.
- **12.** Ročný výkaz A (MZ SR) 18–01 o činnosti neurologických ambulancií za roky 2008 a 2009. Bratislava: Národné centrum zdravotníckych informácií 2009.
- **13.** Parkinson study group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch Neurol 1989; 46(10): 1052–1060.
- **14.** Baba Y, Putzke JD, Whaley NR, Wszolek ZK, Uitti RJ. Gender and the Parkinson's disease phenotype. J Neurol 2005; 252(10): 1201–1205.
- **15.** Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990; 40(5): 763–766.
- **16.** Marras C, Rochon P, Lang AE. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002; 59(11): 1724–1728.
- 17. Fernandez H, Lapane KL, Ott BR, Friedman JH. Gender differences in the frequency and treatment of behavior problems in Parkinson's disease. SAGE Study Group. Systematic Assessment and Geriatric drug use via Epidemiology. Mov Disord 2000; 15(3): 490–496.
- **18.** Poewe W. Dysautonomia and cognitive dysfunction in Parkinson's disease. Mov Disord 2007; 22 (Suppl 17): S374–S378. doi: 10.1002/mds.21681.
- **19.** Klingler H Ch, Heidler H, Madersbacher H, Primus G. Nocturia: an Austrian study on the multifactorial etiology of this symptom. Neurourol Urodynam 2009; 28(5): 427–431. doi: 10.1002/nau.20665.